|
業務類別
|
Biotechnology |
|
業務概覽
|
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong. |
| 公司地址
| Bahnhofstrasse 20, Zug, CHE, 6300 |
| 電話號碼
| +41 417119325 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.oculis.com |
| 員工數量
| 49 |
| Mr. Pall Ragnar Johannesson |
Chief Business Officer |
-- |
04/03/2026 |
| Dr. Riad Sherif, M.D. |
Chief Executive Officer and Director |
-- |
04/03/2026 |
| Ms. Sylvia Cheung |
Chief Financial Officer |
-- |
04/03/2026 |
|
|
| Ms. Geraldine O’Keeffe |
Independent Director |
04/03/2026 |
| Dr. Riad Sherif, M.D. |
Chief Executive Officer and Director |
04/03/2026 |
| Mr. Anthony A. Rosenberg |
Chairman of the Board |
04/03/2026 |
| Ms. Christina M. Ackermann |
Independent Director |
04/03/2026 |
| Mr. Robert K. Warner |
Independent Director |
04/03/2026 |
| Mr. Martijn Kleijwegt |
Independent Director |
04/03/2026 |
| Dr. Arshad M. Khanani, M.D. |
Independent Director |
04/03/2026 |
| Mr. Lionel Carnot |
Independent Director |
04/03/2026 |
|
|
|
|
